Адипокины и их возможная роль в ожирении и сахарном диабете 2-го типа

Литература:
1. Poulos SP, Hausman DB, Hausman GJ. The development and endocrine functions of adipose tissue. Mol Cell Endocrinol 2010; 323(1): 20-34
2. DePaoli AM. 20 years of leptin: leptin in common obesity and associated disorders of metabolism. J Endocrinol 2014; 223 (1):T71-T81
3. Yang J, Kang J, Guan Y. The mechanisms linking adipos-opathy to type 2 diabetes. Front Med 2013; 7 (4): 433-444
4. Amato MC, Pizzolanti G, Torregrossa V, et al. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One 2014; 9 (3): c91969
5. Abranches MV, Oliveira FC, Conceicao LL, et al. Obesity and diabetes: the link between adipose tissue dysfunction and glucose homeostasis. Nutr Res Rev 2015; 28 (2): 121-132
6. Booth A, Magnuson A, Fouts J, et al. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig2015;21 (1): 57-74
7. Krotkiewski M, Billing-Marczak K. Different types of obesity: Can some types of obesity be protective? Pol Merkur Lekarski 2014; 37 (219): 175-180
8. Bays H. Central obesity as a clinical marker of adiposopa-thy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes 2014; 21 (5): 345-351
9. Tchernof A, Despres JP Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93 (1): 359-404
10. Farooq R., Amin S, Hayat Bhat M, et al. Type 2 diabetes and metabolic syndrome: adipokine levels and effect of drugs. Gynecol Endocrinol 2017; 33 (1): 75-78
11. Sattar N, Gill JM. Type 2 diabetes as a disease of ectopic fat? ВМС Med 2014; 12: 123-124
12. LukichA, Gavish D, Shargorodsky M. Normal weight diabetic patients versus obese diabetics: relation of overall and abdominal adiposity to vascular health. Cardiovasc Diabetol 2014; 13(1): 141-145
13. Strohle A, Worm N. [Healthy obesity? Why the adiposity paradox is only seemingly paradox]. Med Monatsschr Pharm 2014; 37 (2): 54-64
14. Kyung MC. Sarcopenia and Sarcopenic Obesity. Endocrinol Metab (Seoul) 2013; 28 (2): 86-89
15. Ishii S, Tanaka T, Akishita M, et al. Metabolic Syndrome, Sarcopenia and Role of Sex and Age: Cross-Sectional Analysis of Kashiwa Cohort Study. PLoS One 2014; 9 (11): e112718
16. El-Mesallamy HO, Hamdy NM, Sallam AA. Effect of obesity and glycemic control on serum lipocalins and insulin-like growth factor axis in type 2 diabetic patients. Acta Diabetol 2013; 50 (5): 679-85
17. Geronikolou SA, Pavlopoulou A, Cokkinos D, etal. Inter-actome of Obesity: Obesidome Genetic Obesity, Stress Induced Obesity, Pathogenic Obesity Interaction. Adv Exp Med Biol 2017; 987: 233-241
18. Kaur Y, de Souza RJ, Gibson WT, et al. A systematic review of genetic syndromes with obesity. Obes Rev 2017; 18 (6): 603-634
19. Holmes MV, Pulit SL, Lindgren CM. Genetic and epigen-etic studies of adiposity and cardiometabolic disease. Genome Med 2017; 9(1): 82-85
20. Goodarzi MO. Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. Lancet Diabetes Endocrinol 2017; S2213-8587 (17) 30200-0
21. Шпаков А. О., Деркач К. В. Меланокортиновая сигнальная система гипоталамуса и ее функциональное состояние в условиях сахарного диабета 2-го типа и метаболического синдрома. Российский физиологический журнал им. И.М. Сеченова 2016; 102(1): 18-40
22. NoakesTD. So What Comes First: The Obesity or the Insulin Resistance? And Which Is More Important? Clinical Chemistry 2018; 64 (1): 7-9
23. Бондарь И. А. Преимущества, безопасность и перспективы применения ситаглиптина у больных сахарным диабетом 2-го типа с хронической болезнью почек. Медицинский совет 2017; (11): 170-175
24. Costa JV, Duarte JS. [Adipose tissue and adipokines]. Acta Med Port 2006; 19 (3): 251-256
25. Fonseca-Alaniz MH, Takada J, Alonso-Vale Ml, et al. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Rio J) 2007; 83 (5 Suppl): S192-S203
26. Шпаков А. О. Лептиновая сигнальная система мозга и ее функциональное состояние в условиях метаболического синдрома и сахарного диабета 2-го типа. Журнал эволюционной биохимии и физиологии 2016; 52(3): 161-176
27. Fujikawa Т, Coppari R. Living without insulin: the role of leptin signaling in the hypothalamus. Front Neurosci 2015; 9: 108
28. Kohara K, Ochi M, Tabara Y, Nagai T, et al. Leptin in sar-copenic visceral obesity: possible link between adipocytes and myocytes. PLoS One 2011; 6 (9): e24633
29. Myers MG, Heymsfield SB, Haft C, et al. Challenges and opportunities of defining clinical leptin resistance. Cell Metab 2012; 15: 150-156
30. Shpakov АО, Derkach KV, Berstein LM. Brain signaling systems in the type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. Future Science OA (FSO)2015; 1 (3): FS025
31. Park HK, Ahima RS. Leptin signaling. FlOOOPrime Rep 2014; 6: 73
32. Koleva Dl, Orbetzova MM, Atanassova PK. Adipose tissue hormones and appetite and body weight regulators in insulin resistance. Folia Med (Plovdiv) 2013; 55 (1): 25-32
33. Knights AJ, Funnell AP, Pearson RC, et al. Adipokines and insulin action: A sensitive issue. Adipocyte 2014; 3 (2): 88-96
34. Yoo HJ, Choi KM. Adipokines as a novel link between obesity and atherosclerosis. World J Diabetes 2014; 5 (3): 357-363
35. Whitehead JP, Richards AA, Hickman IJ, et al. Adiponec-tin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8 (3): 264-280
36. Escote X, Gomez-Zorita S, Lopez-Yoldi M, et al. Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development. Int J Mol Sci 2017; 18 (8): E1770
37. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008; 15(18): 1851-1862
38. Gao Y, Wang C, Pan T, et al. Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats. Arq Bras Endocrinol Metabol 2014; 58 (1): 42-47
39. Alipour FG, Ashoori MR, Pilehvar-Soltanahmadi Y, et al. An overview on biological functions and emerging therapeutic roles of apelin in diabetes mellitus. Diabetes Metab Syndr 2017: 11 (Suppl2):S919-S923
40. Hu H, He L, Li L, et al. Apelin/APJ system as a therapeutic target in diabetes and its complications. Mol Genet Metab 2016; 119 (1-2): 20-27
41. Kuryszko J, Stawuta P, Sapikowski G. Secretory function of adipose tissue. Pol J Vet Sci 2016; 19 (2): 441-446
42. Goralski KB, McCarthy TC, Hanniman EA, etal. Chemer-in, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007; 282 (38): 28175-28188
43. Heiker JT. Vaspin (serpinA12) in obesity, insulin resistance, and inflammation. J Pept Sci 2014; 20 (5): 299-306
44. Bozkurt Dogan S, Ongoz DF, Balh U, et al. Levels of vaspin and omentin-1 in gingival crevicular fluid as potential markers of inflammation in patients with chronic periodontitis and type 2 diabetes mellitus. J Oral Sci 2016; 58 (3): 379-389
45. Kamble PG, Pereira MJ., Sidibeh CO, et al. Lipocalin 2 produces insulin resistance and can be upregulated by glucocor-ticoids in human adipose tissue. Mol Cell Endocrinol 2016; 427: 124-132
46. Guilherme A, Virbasius JV, Puri V, et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9 (5): 367-377
47. Brocker C, Thompson D, Matsumoto A, et al. Evolutionary divergence and functions of human interleukin (IL) gene family. Hum Genomics 2010; 5 (1): 1 -30
48. Katagiri H, Yamada T, Oka Y Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007; 101: 27-39.